1st Quarter - Report
CAPITOL SOLUTIONS for AMGEN USA
Firm
Client
Income
$50,000
Expenses
—
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
H.R. 1548, Pathway for Biosimilars Act of 2009 H.R. 3200, Americas Affordable Health Choices Act; Issues related to the Eshoo amendment, 001, issues related to biosimilars, and Sec. 1232, the End-Stage Renal Disease (ESRD) bundling formula H.R. 3590, The Patient Protection and Affordable Care Act; Issues related to subtitle A, "biologics price competition and innovation H.R. 4872, The Reconciliation Act of 2010
| Lobbyist | Covered position, as disclosed |
|---|---|
| DON LYSTER | — |
| DANIEL C TATE | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.